• The combination of
the new BioResponse technology leads to numerous,
innovative multi-parametric applications for
routine diagnostics and applied research to
displacement of trade rivals at the diagnostics
market up to and including world-wide business
leadership on individual areas like auto-immune
diagnostics, infection serology and molecular
diagnostics. The development of a scientific
concept for multiparametric analytics leads to
achieving leadership of opinion and an
argumentative base for marketing and sales.
• We are developing
the core technology "BioResponse", comprised of
the "VideoScan" measuring system and the test
systems "Bead-Assay," "Cell-Assay" and
"PCR-Array." These technologies are protected by
patents. The BioResponse technology features
cost-efficient materials, high quality test
readings and multi-purpose applicability, which is
leading to a standard system for diagnostic
laboratories.
• The development of a
multitude of possible diagnostic assays has been
started for the multi-parametric analysis of
differential diagnosis of reactive and rheumatic
arthropathies and infections to increase
sensitivity and specificity compared to existing
systems, and to increase the diagnostic
information available for the user. Direct results
are safer therapies with less adverse effects
which directly affects the interests of the
patient and are contribute to reducing the cost of
healthcare.
• The implementation
of new diagnostic strategies, the successful
marketing of new products and maintaining the
rights to the technology and thus the added value
in Lower Lusatia is provided by all partners.
Target group
New products based on this new technology are
aimed at laboratory physicians in clinics and
laboratory practices. In addition, applications
for the life science sector and pharmaceutical
analytics are being planned. For those market
segments the strategic cooperation are still to be
built.